Profile data is unavailable for this security.
About the company
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
- Revenue in CHF (TTM)8.33bn
- Net income in CHF952.13m
- Incorporated2018
- Employees25.32k
- LocationAlcon AGRue Louis d'Affry 6FRIBOURG 1701SwitzerlandCHE
- Websitehttps://www.alcon.ch/
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 13.36m | 2.67% |
| Aristotle Capital Management LLCas of 30 Jun 2024 | 13.03m | 2.61% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 12.35m | 2.47% |
| UBS Asset Management Switzerland AGas of 30 Jun 2024 | 11.82m | 2.37% |
| Harding Loevner LPas of 30 Jun 2024 | 9.66m | 1.93% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 9.05m | 1.81% |
| ClearBridge Investments LLCas of 30 Jun 2024 | 9.04m | 1.81% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jun 2024 | 8.53m | 1.71% |
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 6.46m | 1.29% |
| AKO Capital LLPas of 30 Jun 2024 | 6.37m | 1.28% |
